I have chosen two cell lines that represent the spectrum of bladder cancer cell lines: UMUC-3 and RT4. The former is a mesenchymal, high-grade, and a luminal tumor. The latter is an epithelial, low-grade, and a basal tumor. In summary, these cell lines represent some of the most difficult bladder tumors to treat but have unique features along the EMT spectrum and sensitivity to EGFR-based therapy that will help identify subtle differences among therapeutics. However, since they are relatively resistant to cisplatinum-based chemotherapy, they will hopefully identify new targets for bladder tumors refractory to standard of care therapy. Furthermore, these cell lines have been well-characterized in the literature and have sequenced in publically available cancer cell line databases. Using the platform established by Lou Stadt's group, we will screen 2000+ drugs against these cell lines to identify a novel agent. We will then explore in detail therapeutics identified by this strategy.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Scientific Cores Intramural Research (ZIC)
Project #
1ZICBC011531-01
Application #
8763785
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
1
Fiscal Year
2013
Total Cost
$10,555
Indirect Cost
Name
National Cancer Institute Division of Basic Sciences
Department
Type
DUNS #
City
State
Country
Zip Code